A propos Startup365

Chaque jour nous vous présenterons une nouvelle Startup française ! Notre pays regorge de talents et d'entrepreneurs brillants ! Alors partons à la découverte des meilleures startup françaises ! Certaines d'entre elles sont dans une étape essentielle dans la vie d'une startup : la recherche de financement, notamment par le financement participatif (ou crowdfunding en anglais). Alors participez à cette grande aventure en leur faisant une petite donation ! Les startups françaises ont besoin de vous !

Top 5 Resume Tips to help you get a job as an Account Manager

From startups to MNCs, everyone needs an account manager. 

This means that getting an Account Manager job comes with maximum competition. Millions of people are fighting tooth and nail to achieve the same dream, making it extremely difficult to land the job.

This is where your resume comes in. You need an impeccable Account Manager Resume to beat the competition and get the job that you have always wanted. 

In this article, we’ll show you how to optimize your resume using 5 easy tips.

So, without further ado, let’s see what these top 5 tips are. 

  1. Organize your resume under relevant sections

Knowing what to put in your account manager resume matters. Knowing how to organize the information you put in your resume matters more.

It is very important that your account manager resume has the right information and it is equally important that your resume organizes information under the correct sections. 

Doing this helps you write a resume that is easy to read and comprehend.

Organizing information under the appropriate section also has the added advantage of helping you present information in an optimal manner. 

So here’s a list of the must-have sections for your Account Manager Resume:

  • Header
  • Profile Title
  • Personal Information 
  • Summary 
  • Key Skills 
  • Technical Skills
  • Professional Experience
  • Education
  • Certifications (if any)
  • Additional Information (if any)
  1. Use the reverse chronology format

Your most recent work experience is the experience that matters most.

For example: 

Your current work experience as an Account Manager in your current organization is more relevant to your career than your work experience in the old organizations you were affiliated with in the past.

This is why you should use the reverse chronological format to structure your resume. 

It helps you organize the content of your resume according to the order of relevance. Using this format, your most recent work experience is featured first, followed by the second most recent work experience and so on and so forth.

However, this is not limited to your professional experience alone, but this order is uniformly implemented throughout your resume.

  1. Customize your resume as per the job description

This might come as a rude shock to you but you’re doing it all wrong if you’re sending the same generic resume to everyone.

Each job profile comes with a unique set of job specifications and requirements.

This is why it is important to tailor your resume according to each  job that you are targeting. Recruiters will hate it if you send an uncustomized resume while applying for every job. 

For example, company x may look for Account Managers with a certain certification, while company y might look for a minimum number of job experience.

Based on the company you are targeting, it is important to customize your resume accordingly.

This means including all the skills given in a particular job description and listing them under the Key Skills section of your resume, given you actually possess these skills.

  1. Endorse your skills in your account manager resume

As an Account Manager, it is your skills that do the talking for you.

Ultimately a recruiter is concerned with your skill sets and if your skills would bring value to the organization they are hiring for.

So you should make a show of your skills.

It will do you good to organize your skills under the “Key Skills” section of your Account Manager Resume.

Here’s an example of what this section should look like in your resume:

  1. Make the most of your professional experience section

Recruiters love nothing more than to learn how you can benefit the organization. They don’t want to know what your roles you performed, but how this role helped the organization.

For example, being good at managing accounts is of no use if you’re not able to deliver value using this skill set. 

This is why it is extremely important for an account manager to be vocal about the value they can deliver. At the end of the day, that’s all that matters.

So while drafting the professional experience section of your resume, make sure that you don’t just robotically summarize your roles & responsibilities.

Instead, focus on these 3 things:

  • Readability
  • Effectiveness

Readability

The hallmark of a great resume is great readability. If the recruiter does not read your resume, there is no point in writing one. To avoid this blunder, make use of crisp one-liner points to talk about your roles & responsibilities.

Effectiveness

Your resume is of no use if it fails to create an impact. 

To ensure that delivers impact, draw a connection between the roles you performed and the visible results of your roles & contributions using achievement figures. 

For example: 

“Collaborated with analytics department to determine root causes of customer complaints and reducing them by 20%”

In the above example, you explained the following:

  • Task you performed: Collaborated with analytics department
  • Why you performed the task: Determine root causes of customer complaints
  • Results: Reduced customer complaints by 20%”
  1. Conclude your resume with a powerful summary

Your Account Manager Resume is incomplete without a powerful resume summary as it is your summary which helps you give an overview of your professional life. 

A recruiter does not have all the time in the world to evaluate your resume from top to bottom. 

They might end up simply evaluating your summary to get a quick glimpse of your professional trajectory in one go.

So while writing your resume, focus on the aspects of your professional life that makes you fit for the job. Talk about your achievements and your key expertise areas. 

Here’s an outline of the top things to keep in mind while drafting this:

  • Begin your summary with a quick mention of  your work experience
  • Mention your latest professional job designation
  • Talk about your key expertise areas
  • Try to show why you performed the roles you performed

Taking all the above points into account, here’s an example of what the ideal summary for an Account Manager should look like:

“5+ years experienced Account Manager highly skilled in financial accounting, budget preparation and team management with a proven track record in achieving top and bottom-line profitability. Adept at strategizing with other departments to develop solutions like troubleshooting customer complaints to refine the company’s customer care & support services. Proficient in vetting staff for the finance department and training them for managing accounts.”

Key Takeaways

To sum it up:

  • How you present information matters. So organize your information under relevant sections.
  • Your most recent work experience should be prioritized. 
  • Make a unique resume for each job that you’re targeting.
  • Make a seperate skills section to outline your account management skills.
  • Your resume should be readable and effective. Use achievement figures to highlight the results of your contributions.
  • Write a powerful summary which briefly sums up your achievements.

#UK Kymab wins Supreme Court patent victory over US giant

//

Cambridge biopharma business Kymab has won a landmark UK Supreme Court verdict that invalidates patent claims by US giant Regeneron.

It is the latest court victory for the Babraham-based antibodies powerhouse over its New York rival.

With investment totalling $220 million Kymab is using its antibody platforms to realise new opportunities in therapeutic antibodies and vaccine development.

Kymab reveals that the Supreme Court of the United Kingdom has held that all of the claims of two patents (European Patents EP(UK) 1 360 287 and EP(UK) 2 264 163, the ‘Murphy patents’) owned by Regeneron Pharmaceuticals Inc that were asserted against Kymab are invalid.
 
The court’s decision upholds the February 2016 verdict of the High Court trial judge, Mr. Justice Henry Carr to revoke the claims and reverses the Appeal Court’s determination that they were valid. 

A five-member panel of the Supreme Court heard arguments in February and announced their decision today. It was held that the relevant claims of the Murphy patents were invalid for insufficiency because they did not enable the ordinary skilled person to work the claimed invention across the breadth of the claims, in line with established jurisprudence of the UK courts and European Patent Office. 

The Supreme Court noted that Kymab’s ability to create transgenic mice with the entire human antibody variable region depended upon Kymab’s own inventions made separately after the priority date of the Murphy patents.

Kymab CEO Simon Sturge said: “We are grateful that the Court has recognised the shortcomings of the Regeneron patents and reinforced the established law that requires that an invention is adequately enabled across its scope. 

“Kymab’s IntelliSelect® platforms continue to generate best‑in‑class, fully human monoclonal antibodies, underpinned by our extensive IP estate.”

Dr Penny Gilbert, partner at Powell Gilbert LLP, added: “This case raised fundamentally important questions of patent law relevant to a wide variety of innovative life science companies in the UK. 

“The Supreme Court has confirmed that patents should not be available for inventions that are not adequately enabled. Kymab has shown tremendous resilience in defending this case since Regeneron commenced proceedings in September 2013 and we are pleased to have helped them achieve this great result.”

The Murphy patents sought to cover genetically modified mice containing chimeric human-mouse antibody genes and the human antibodies made using such mice. 

The European Patent Office had previously upheld the patents but had not considered evidence that was available to the UK Courts. Counterparts of the Murphy patents have also been litigated by third parties in the US where an equivalent Murphy patent was found to be invalid. 

Kymab’s patent estate provides protection in the United States, Europe, Japan and other globally important commercial markets for human antibody therapeutics. 

Its patents cover human antibodies produced using transgenic platforms that employ chimeric human-mouse antibody genes. In September 2019 and January 2020, Regeneron filed requests at the US Patent Office’s PTAB (Patent Trial & Appeal Board) seeking Inter Partes Review (IPR) proceedings against 5 of Kymab’s US patents. 

The PTAB rejected all five petitions filed by Regeneron leaving each patent and their claims in full force in the US. Regeneron filed oppositions against Kymab’s Japanese patents, but these patents were upheld in unappealable decisions by the Japanese Patent Office. 

In August 2019 the Australian Patent Office (IP Australia) rejected on all grounds an opposition by Regeneron against Kymab’s patent protecting therapeutic antibodies produced from transgenic mouse platforms. Regeneron appealed to the Australian Federal Court, but in May 2020 Regeneron agreed to dis­continue its appeal and Kymab’s Australian patent is now upheld and in force.

from Business Weekly https://ift.tt/31dzV7K

Publié dans #UK

#UK Siemens pays millions for Cambridge’s UltraSoC

//

Cambridge chip technology business UltraSoC has been acquired by Texas-headquartered Siemens Digital Industries Software.

While no sum has been officially announced for the acquisition it runs into the multimillions, Business Weekly understands.

It is understood that UltraSoC will continue in Cambridge and that CEO Rupert Baines will stay at the helm in Cambridge immediately following the sale.

UltraSoC provides instrumentation and analytics solutions that put intelligent monitoring, cybersecurity and functional safety capabilities into the core hardware of system-on-chip. 

Siemens has bought UltraSoC to drive design for silicon lifecycle management. It plans to integrate UltraSoC’s technology into the Xcelerator portfolio as part of Mentor’s Tessent™ software product suite. 

The addition of UltraSoC to Siemens enables a unified data-driven infrastructure that can enhance product quality, safety and cybersecurity, and the creation of a comprehensive solution to help semiconductor industry customers overcome key pain points including manufacturing defects, software and hardware bugs, device early-failure and wear-out, functional safety, and malicious attacks.

Brady Benware, Tessent Vice-President and General Manager, Siemens Digital Industries Software, said: “Siemens’ acquisition of UltraSoC means that for the first time our customers can access not just design-for-test, but a comprehensive ‘Design for Lifecycle Management’ solution for system-on-chips, including functional safety, security and optimisation.

“By utilising design augmentation to detect, mitigate and eliminate risks throughout the SoC lifecycle, customers can radically improve time-to-revenue, product quality & safety, and profitability. 

“UltraSoC has a fast-growing business and impressive customer list and, as part of Siemens, can complement Tessent to create a truly unique offering in the market.”UltraSoC in Cambridge

The combination of Siemens and UltraSoC technology can benefit the entire semiconductor product lifecycle, including structural, electrical, and functional capabilities of SoCs. It also supports Siemens’ comprehensive digital twin with UltraSoC providing monitoring of the real device.

UltraSOC CEO Rupert Baines added: “This acquisition accelerates UltraSoC’s vision at a much larger scale with the incredible team, assets, industry know-how and footprint of Siemens.

“Being part of one of the world’s foremost technology companies will allow UltraSoC to better serve our customers by accelerating R & D, leveraging a much larger pool of go-to-market resources, and an enormous global infrastructure.

“It has been clear since our initial meeting that UltraSoC and Siemens share a vision on how technology businesses can transform their operations end-to- end, from design conception to field deployment and we are excited to join the community.”

He added in a blog: “What a momentous day this is. After five years in the role of CEO at UltraSoC, I am proud that we have agreed to become a part of Siemen, in a move that we knew made perfect sense from the time of our first meetings. It is striking just how clearly aligned our visions are.

“The pieces of the jigsaw fit together so nicely: UltraSoC’s technology and history with its customers; where Tessent is coming from and its market-leading design-for-test offering; and the broader vision of Siemens Digital Industries. 

“The combination takes us to another level: product lifecycle management is such a significant big-picture opportunity, as is cybersecurity and the concept of the Digital Twin. 

“Tessent and UltraSoC bring the core semiconductor element to that broader story, making it perfectly balanced. Tessent brings IP into the chip to improve test and manufacturability; UltraSoC enhances the validation process and extends that into field deployment. Overall, the combination enables a truly complete design for product lifecycle offering.

“Our people are spread around the world: in Cambridge and Bristol in the UK; in the US, Poland, China and Japan. Our geographical diversity means that we’ve actually never all been in the same place at the same time!

“The fact that Siemens has recognised our value is testament to the talent, hard work and the success of the entire organisation.

“Over five years, we’ve announced some incredible customer wins that have demonstrated the traction for our technology across security applications, automotive, enterprise IT, artificial intelligence and machine learning (AI/ML). We’ve put significant effort into developing strong industry presence through strategic partnerships.

“As is the nature of the industry and the technology companies we sell into, we are under NDA with many customers and will never be able to publicly declare many of the major names in the technology industry who trusted us and decided to use our technology in the last few years. But our thanks to all of those customers and partners who have believed in us so strongly.”

UltraSoC‘s products are widely used in the automotive, high-performance computing, storage and semiconductor industries. The company was recently selected as a participant in the DARPA AISS (Automatic Implementation of Secure Silicon) program and is a member of the Secure-CAV consortium – an ambitious collaborative project that aims to improve the safety and security of tomorrow’s connected and autonomous vehicles. 
Siemens’ acquisition of UltraSoC is due to close in the fourth quarter of Siemens’ fiscal year 2020. 

Siemens Digital Industries Software is driving transformation to enable a digital enterprise where engineering, manufacturing and electronics design meet tomorrow. 

The Xcelerator portfolio helps companies of all sizes create and leverage digital twins that provide organisations with new insights, opportunities and levels of automation to drive innovation.

from Business Weekly https://ift.tt/2YqF0aZ

Publié dans #UK

#UK Arm ousts Intel at heart of Apple’s new Mac magic

//

US tech titan Apple is celebrating Independence Day early – and for long-term Cambridge UK partner Arm the outcome is just Yankee Doodle Dandy.

Thirty years after Apple backed a fledgling Arm to break free from Acorn it has decided to produce its own processors as the heart of its future Mac computers – and will ditch the Intel insides to base the new models on Arm architecture.

As an example of a virtuous circle the new Arm-Apple alliance takes some beating. Apple is building a new, dedicated R & D nerve centre in Cambridge which continues to be the springboard for Arm’s relentless global growth.
Apple already uses ARM designs in smartphones and mobile tablets, including the iPhone and iPad.

Apple revealed at its World Wide Developers Conference, held virtually for the first time due to the coronavirus pandemic, that the first silicon-based Mac would ship by the end of 2020 and based on Arm IP.

The full transition will probably take two years, which gives developers time to modify the relevant apps.

For Apple the benefits are many and obvious; with its proprietary Arm-based chips it will control future development of its hardware and software just as it does with the iPhone and iPad offerings.

And for users the upside is massive: nextgen Macs will be extremely powerful and ultra efficient with longer battery life and the potential for built-in mobile broadband.

Apple says the move will also enhance security and enable the company to leverage novel tech innovations like the the AI neural engine and some unparalleled graphics capability. 

Continually refined Arm graphics tech is already being used to accelerate innovation across a broad raft of industries, not least in automotive. 

Tim Cook, Apple’s CEO, said: “From the beginning the Mac has always embraced big changes to stay at the forefront of personal computing. Announcing our transition to Apple silicon makes this an historic day for the Mac. 

“With its powerful features and industry-leading performance, Apple silicon will make the Mac stronger and more capable than ever. I’ve never been more excited about the future of the Mac.”

from Business Weekly https://ift.tt/3fNyj8Y

Publié dans #UK

#UK CIC piles on the assets in boom year for investments

//

Cambridge Innovation Capital expanded its portfolio to 30 companies and increased net asset value by 46 per cent to £301.7 million in the year to March 31.

The successes included one unicorn (CMR Surgical) and CIC’s first IPO courtesy the NASDAQ float by Bicycle Therapeutics.

CIC invested £35.7m into four new and 12 existing portfolio companies, bringing the total invested to £163m. It cites a fair value increase of £69.5m (2019: £30.7m) which, together with investments, resulted in a portfolio value of £291.5m (£186.3m). CIC adds that £42.5m (£38.6m) was drawn down from the £150m committed by shareholders in the year to March 31, 2019.

CIC welcomed Riverlane, Sense Biodetection, PredictImmune and Immutrin to its family of portfolio companies – plus PetMedix post-period.

Bicycle Therapeutics conducted its NASDAQ IPO to progress its programmes, including toxin drug conjugates and immune modulators, to treat cancer and other debilitating diseases.

CMR Surgical closed a £195m Series C funding round to commercialise its next generation surgical robotic system and hit unicorn status ($1 billion valuation).

Managing partner Andrew Williamson was thrilled by CIC’s progress. He said: “Despite the recent challenges posed by the global coronavirus pandemic, we have made tremendous progress during the year.

“Our portfolio now includes one company valued in excess of £1 billion and another that has listed on NASDAQ, our first IPO. We have expanded the number of companies in, and value of, our portfolio, enhanced our potential deal flow with the creation of two accelerators and augmented our team to support the growth of the business.”

In addition to the Bicycle and CMR successes, CIC participated in a £6.5m Series A funding for AudioTelligence, which is dedicated to making speech clear and intelligible in a noisy world. 

AudioTelligence’s technology acts like autofocus for sound, using data-driven ‘blind audio signal separation’ to focus on the source of interest, allowing it to be separated from interfering noises. This enables microphones to focus on what users are saying, improving the audio quality for listeners, regardless of background noise.

CIC also backed Cytora, which closed a £25m Series B to continue developing its artificial intelligence-powered insurance technology platform that enables insurers to underwrite more accurately, reduce frictional costs and achieve profitable growth. 

CIC led a £3.3m seed round for Riverlane, a quantum computing software developer transforming the discovery of new materials and drugs. Cambridge Enterprise, the commercialisation arm of the University of Cambridge, also participated. 

Riverlane’s software leverages the capabilities of quantum computers, which operate using the principles of quantum mechanics. 

CIC co-led a £12.3m Series A in Sense Biodetection, alongside Earlybird, to allow the business to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests – a pioneering new class of diagnostic product.  

During the year CIC also announced the launch of Start Codon and established DeepTech.labs – two new accelerators focused on accelerating the translation of world-class research into commercially successful companies. 

Post-period CIC invested in PetMedix, a Cambridge UK-based biopharma company developing antibody-based therapeutics for companion animals; it was CIC’s first investment in the animal health space. 

PetMedix has developed an innovative platform for the creation of naturally generated, fully species-specific therapeutic antibodies, enabling the discovery of its own veterinary medicines to target some of the most important clinical areas in animal health.

from Business Weekly https://ift.tt/3fMwrxd

Publié dans #UK

#UK Illumina unveils first Cambridge cohort for global genomics accelerator

//

Two Cambridge companies fly the flag for the UK cluster in the first global cohort of Illumina’s genomics accelerator.

Alchemab Therapeutics and Tailor Bio are among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK.

Four more companies will join as part of the 11th funding cycle in the San Francisco Bay Area where the initiative was established and has thrived. 

The global company creation engine, focused on partnering with entrepreneurs to build breakthrough genomics startups, announced its global expansion last year.

As Business Weekly reported then, it is the first time the venture has been taken outside Illumina’s US heartland with the American genomics giant choosing its Granta Park Cambridge campus as nervecentre for the initiative’s UK bow.

Due to lockdowns and travel restrictions during the COVID-19 pandemic, Illumina Accelerator kicked off both funding cycles digitally this month, bringing all seven startup companies together for the first time.

During two, six-month funding cycles per year, Illumina Accelerator provides selected startups with access to seed investment, and Illumina sequencing systems and reagents, as well as business guidance, genomics expertise and fully operational, newly refurbished lab space adjacent to Illumina’s campuses in Cambridge UK or the San Francisco Bay Area. 

The newest companies to join Illumina Accelerator’s portfolio of genomics startups are as follows – in Cambridge:-

  • Alchemab Therapeutics, an antibody therapeutics company exclusively featured in Business Weekly recently, which is harnessing the naturally protective power of patient antibodies to keep people free from hard-to-treat disease in a unique approach to drug discovery and development.
  • Neurolytic Healthcare, a diagnostics company from Oxford focused on delivering digital, genomics-driven diagnostics and personalised treatment recommendations for neurological conditions.
  • Tailor Bio, a Cambridge oncology diagnostics company spun out of Cancer Research UK-funded research, which is developing a proprietary precision oncology platform to identify patterns in tumour DNA to predict a patient’s response to cancer drugs.

And in the SF Bay Area:-

  • AarogyaAI Innovations Pvt., a diagnostics company from India which comprehensively diagnoses drug-resistance in tuberculosis rapidly, enabling the most effective therapies for patients.
  • MEDIC Life Sciences Inc., a drug discovery company in the Bay Area, which is building a pre-clinical testbed of millions of tumuor samples based on CRISPR and cancer organoids to enable personalised targeted therapies for cancer with maximised clinical success rates.
  • Pluton Biosciences, LLC, a microbial testing and discovery research company in St Louis, developing eco-friendly natural products mined from unique bacteria, fungi and viruses to replace synthetic chemical applications in agriculture and pest control.
  • WellSIM Biomedical Technologies, Inc., a tools company from the Bay Area, which is developing a high-throughput automated exosome processing instrument based on microfluidics allowing unparalleled isolation efficiency, purity and integrity for use in therapeutic and clinical diagnostics applications.

Amanda Cashin, co-founder and global head of Illumina Accelerator, said: “As we navigate the current global pandemic there is an even stronger urgency to create breakthrough genomics startups that will transform human health and beyond. 

“By opening our second location and partnering with seed stage capital investors, we are proud to invest in these transformative startups to push the boundaries of where genomics can go.”

Illumina Accelerator has partnered with First In Ventures to provide convertible notes for the incoming startups in the US and UK. Wing Venture Capital will continue its support in providing convertible notes in the US and Cambridgeshire & Peterborough Combined Authority will support the companies in the UK. 

Paula Dowdy, Illumina’s senior vice-president and general manager, EMEA, said: “We believe the startups selected have great potential to expand the genomics ecosystem and deliver new and important applications to market.
“The UK is a leader in genomics research and we’re delighted to locate the extension of Illumina Accelerator at our new campus in Cambridge.”

Illumina Accelerator is the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry.

Since launching in 2014, Illumina Accelerator has invested in 45 genomics startups from across the globe, which have collectively raised approximately $400 million in venture capital funding.

Applications are being accepted for the next global funding cycle. These are due by August 1, 2020. Up to five companies will be chosen in each location. To apply, visit illumina.com/science/accelerator.html

from Business Weekly https://ift.tt/2zUItoW

Publié dans #UK

#Asia #Japan DJ Selects: Why startups lose control of their sales channels, and how to fix it – Allen Miner – Oracle

//

Oracle first came into Japan more than 25 years ago, but the challenges they faced and overcame then are exactly the same ones firms are facing today in executing their Japan market entry.

Allen explains why Oracle needed a unique sales and marketing strategy for Japan, and how he managed to get buy-in from headquarters — even though Oracle already had a sales and marketing program that had proven fantastically successful in other markets.

We also talk about how Oracle managed to negotiate a amicable exit out from their exclusive distribution agreements not just once, but twice. That’s an amazing accomplishment considering that many foreign companies have destroyed their Japanese business the first time they attempt it.

But Allen, tells the story much better than I do. I think you’ll enjoy the interview. I know I did.

[shareaholic app=”share_buttons” id=”7994466″] Leave a comment
Transcript
Welcome to disrupting Japan. Straight talk from Japan’s most successful entrepreneurs.

I’m Tim Romero, and thanks for joining me.
Update
Japan is slowly opening up again. The official “unofficial” lockdown ended at the beginning of June. Restaurants, bars, and shops are reopening with a lot if plastic curtains and sheeting separating patrons and proprietors.  It’s a long way from normal, but it’s better than being stuck in the house.

International travel is mostly shut down, but domestic travel is really picking up. It seems most of the hotels and resorts in Okinawa are already booked solid for the summer by Japanese who would normally be flying to Hawaii. And Okinawans, grateful for the business, but still nervous about the virus, have some pretty mixed feeling about that.

And of course, with international travel shut down, and all the trade shows canceled, most foreign startups have put their Japan market entry plans on hold. And that’s normally a lot of activity. If you are a B2B startup you need to be looking at Japan. It can be a hard market to crack, but it’’s a lucrative one.

So today, I want to re-share what is one of the most amazing Japan market-entry stories of all time. It has ambition, misdirection. drama, serious career-risk, and rock-concerts.  It’s an old story, but a good one. The technologies have changed since then, but the challenges and the strategies haven’t.
Intro
To kick things off today, we’ll get a chance to sit down and talk with my good friend Allen Miner about the challenges Oracle faced, and overcame, when breaking into Japan.

I’ll warn you in advance that this episode is longer than most, and believe me, I cut things to the bone. But there is just too much great information about how to overcome both the personal and professional challenges that foreign companies face here. I felt like I would be cheating you if I edited out any more. In fact, Allen explains how Oracle successfully maneuvered out of an exclusive distribution agreement, not only once, but two separate times. This is something that has sunk more than one foreign company here. But Allen tells the story much better than I can, so let’s get right to the interview.

[pro_ad_display_adzone id=”1411″ info_text=”Sponsored by” font_color=”grey” ]
Interview
Tim: So I’m sitting down here with Allen Miner and Allen, you’ve been involved with the market entry of a lot of companies into Japan. But today I want to focus on the one that you led personally, which was Oracle Japan. So let’s back up. What was attractive about the Japanese market? What made Oracle decide that they needed to be in this country?

Allen: Actually, that happened a few years before I joined Oracle. In, I believe it was 1982, Oracle was about a $5 million a year company worldwide, 5 years old as a company, and just released their first commercial version of the Oracle database software. There was quite a bit of press about, “How interesting is this relation to technology? It doesn’t require traditional programming to do data manipulation…

from Disrupting Japan: Startups and Innovation in Japan https://ift.tt/2Nn7NXG

#UK Cambridge AI firm says drug identified in April could have saved 5,000 lives

//

Dr David Cleevely

AI VIVO, the Cambridge company combining systems pharmacology and AI to accelerate drug discovery, reveals that its platform correctly identified dexamethasone as having high potential for the treatment of COVID-19 as early as April. 

Had it been adopted earlier in the pandemic it could have saved up to 5,000 lives, the company says. Now it is set to reveal other drugs it believes could help kill coronavirus.

It says this demonstrates the ability of the platform to systematically and correctly identify candidates with the highest chance of therapeutic success.

The low-dose steroid treatment dexamethasone has been part of the world’s biggest trial testing existing therapeutics that could be repurposed to help treat COVID-19.

The drug, which is inexpensive and widely available, was shown to save the lives of seriously ill patients at a late stage of coronavirus. This is being viewed globally as a major breakthrough in the fight against the deadly virus.

On April 16, AI VIVO publicly named dexamethasone, along with four other drugs, as compounds most likely to be effective in treating COVID-19. It is believed that had dexamethasone been used to treat patients in the UK from the start of the pandemic, up to 5,000 lives could have been saved.

To identify the candidate drugs most likely to be effective in treating the disease, AI VIVO used samples from COVID-19 infected cells to build its model for the disease, which was then used to rank thousands of compounds. 

The AI VIVO prediction engine, which is powered by AI, took just 15 days to rank 90,000 compound models in order of efficacy and identified a shortlist of top candidate drugs in April.

AI VIVO’s ranking system is based on its unique phenotypic drug discovery methodology and does not rely on any prior knowledge or known information related to the disease or compounds. 

The company’s April announcement was the first output of the prediction engine and was followed by a wider list of 41 top-ranked candidates on May 7 that are currently in clinical trials for COVID-19. AI VIVO is tracking the clinical trials outcomes for these.

Dr Peyman Gifani, AI VIVO founder and CEO, said: “This is another great validation of AI VIVO’s phenotypic approach to modelling diseases and the effects of drugs. 

“We also believe there are combinations of other top-ranked drugs that with Dexamethasone will be more effective than any single drug, and we are keen to share these combinations with pharma companies and clinical trial investigators to support the fight against COVID-19. 

“We are expanding our interactions with government agencies and pharmaceutical companies to consider the top ranked drugs which have not yet been selected for trials, but have the potential to make a real difference in the fight against COVID-19.” 

Dr David Cleevely, lead investor in AI VIVO, added: “We are pleased to see that AI VIVO has once again been shown to have identified a breakthrough anti COVID-19 drug demonstrated to save lives around the world. 

“This shows the unique capability of AI VIVO’s disruptive technology and the wider applications of this approach for other disease areas.”

AI VIVO has been in contact with various clinical trial investigators including the UK’s ACCORD programme to provide insights for selecting the best drug combinations systematically. 

The advanced technology business now plans to release the names of other generic top ranked drugs that are not currently in clinical trials in order to help the fight against COVID-19. The list will be available on the AI VIVO website. 

AI VIVO has not disclosed a number of proprietary top ranked compound candidates currently in phase II or phase III clinical trials for other indications. 

It is contacting pharma companies who have developed these compounds to provide more information on why the compounds are top-ranked and how they might be used as single drugs and in combinations.

from Business Weekly https://ift.tt/3hzNnsB

Publié dans #UK

#UK Avacta hopeful for potential COVID-19 therapy after test triumph

//

A potential new therapy for COVID-19 infection appears to have moved closer after specific tests on Cambridge-based Avacata’s Affimer biotherapeutics and reagents.

Collaborative work with the Centre for Virus Research at Glasgow University has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein prevent infection of human cells by a SARS-COV-2 model virus.

Avacta recently reported that several of the Affimer reagents that had been generated to develop COVID-19 antigen tests inhibited the interaction between the coronavirus’ spike protein and a receptor found on human cells, called ACE2, which the virus spike protein binds to as the first step in infecting cells.

Avacta has now successfully completed the initial phase of a collaboration with Professor David Bhella at the University of Glasgow showing that these neutralising Affimer reagents prevent a SARS-COV-2 model virus from entering human cells.

Affimer reagents have key benefits compared with antibodies as virus neutralising therapies. Their small size and high solubility means that a much higher concentration of Affimer molecules can be used in the drug formulation to more effectively block the spike proteins on each virus particle and better protect the patient.

Bispecific and trispecific Affimer neutralising therapies that bind to more than one part of the spike protein could ensure the effectiveness of the neutralising therapy even if the virus’ spike protein mutates.

Work is continuing with Professor Bhella to further study the way in which the Affimer reagents prevent infection and Avacta is using this growing body of data actively to secure a large pharmaceutical partner to develop these potential therapeutic candidates rapidly.

Dr Alastair Smith, CEO of Avacta Group, said: “I am delighted that our collaborators at the University of Glasgow have confirmed that these Affimer reagents not only block the spike-ACE2 binding but efficiently prevent a SARS-COV-2 model virus from entering human cells.

“This is critical information that will help to establish a license deal with a large pharmaceutical partner that has the resources to carry out an accelerated clinical development programme.

“Neutralising therapies could be given to those exposed to the virus, such as health and social-care workers, to prevent infection, as well as to patients already infected by the virus, to help treat and prevent disease progression. 

“There is ongoing significant investment by large pharmaceutical companies such as AstraZeneca, GSK, Boehringer Ingelheim and others to develop neutralising therapies for COVID-19.

“We continue to make very good progress across all of our COVID-19 related programmes, as well as our other diagnostic and therapeutic activities, and I look forward to providing further updates in the very near future.”

Professor Bhella added: “There is significant interest around the world in neutralising therapies for COVID-19 given the uncertainties around the timeline for developing an effective vaccine and deploying it. 

“The infectivity assays that we have carried out with the Affimer reagents have gone very well and they show that there are a number of them that are potent inhibitors of a SARS-COV-2 model virus entry into human cells. 

“Given the excellent performance of these novel reagents in the assays, and the other benefits of Affimer reagents, there should be considerable interest from potential partners in developing them as a therapy for COVID-19.”

from Business Weekly https://ift.tt/3edE67p

Publié dans #UK